Invuity, Inc. Forecasted to Post FY2019 Earnings of ($1.44) Per Share (IVTY)
Invuity, Inc. (NASDAQ:IVTY) – Equities researchers at William Blair issued their FY2019 earnings per share estimates for Invuity in a report released on Wednesday. William Blair analyst K. Krum forecasts that the medical instruments supplier will post earnings per share of ($1.44) for the year.
Invuity (NASDAQ:IVTY) last posted its quarterly earnings data on Tuesday, February 13th. The medical instruments supplier reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. The company had revenue of $11.23 million during the quarter, compared to analysts’ expectations of $11.84 million. Invuity had a negative net margin of 100.75% and a negative return on equity of 279.04%.
Invuity (IVTY) traded up $0.05 during trading hours on Thursday, reaching $4.15. 158,190 shares of the company’s stock were exchanged, compared to its average volume of 314,024. The company has a debt-to-equity ratio of 5.39, a current ratio of 2.90 and a quick ratio of 2.47. Invuity has a one year low of $3.70 and a one year high of $9.70.
Large investors have recently bought and sold shares of the business. CAPROCK Group Inc. boosted its position in Invuity by 28.6% in the 3rd quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 10,000 shares during the last quarter. OxFORD Asset Management LLP bought a new position in shares of Invuity during the second quarter worth about $374,000. Vanguard Group Inc. lifted its position in shares of Invuity by 16.3% during the second quarter. Vanguard Group Inc. now owns 402,680 shares of the medical instruments supplier’s stock worth $2,919,000 after purchasing an additional 56,527 shares during the last quarter. Discovery Group I LLC lifted its position in shares of Invuity by 9,587.9% during the third quarter. Discovery Group I LLC now owns 1,258,849 shares of the medical instruments supplier’s stock worth $11,204,000 after purchasing an additional 1,245,855 shares during the last quarter. Finally, Lyon Street Capital LLC lifted its position in shares of Invuity by 15.5% during the third quarter. Lyon Street Capital LLC now owns 883,355 shares of the medical instruments supplier’s stock worth $7,862,000 after purchasing an additional 118,825 shares during the last quarter. 67.57% of the stock is owned by institutional investors.
Invuity Company Profile
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.